



## Discover Generics

Cost-Effective CT & MRI Contrast Agents



WATCH VIDEO

# AJNR

This information is current as of June 18, 2025.

## **Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?**

S. Fellah, D. Caudal, A.M. De Paula, P. Dory-Lautrec, D. Figarella-Branger, O. Chinot, P. Metellus, P.J. Cozzone, S. Confort-Gouny, B. Ghattas, V. Callot and N. Girard

*AJNR Am J Neuroradiol* 2013, 34 (7) 1326-1333

doi: <https://doi.org/10.3174/ajnr.A3352>

<http://www.ajnr.org/content/34/7/1326>

# Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?

S. Fellah, D. Caudal, A.M. De Paula, P. Dory-Lautrec, D. Figarella-Branger, O. Chinot, P. Metellus, P.J. Cozzone, S. Confort-Gouny, B. Ghattas, V. Callot, and N. Girard



## ABSTRACT

**BACKGROUND AND PURPOSE:** Pretherapeutic determination of tumor grade and genotype in grade II and III oligodendroglial tumors is clinically important but is still challenging. Tumor grade and 1p/19q status are currently the 2 most important factors in therapeutic decision making for patients with these tumors. Histopathology and cMRI studies are still limited in some cases. In the present study, we were interested in determining whether the combination of PWI, DWI, and MR spectroscopy could help distinguish oligodendroglial tumors according to their histopathologic grade and genotype.

**MATERIALS AND METHODS:** We retrospectively reviewed 50 adult patients with grade II and III oligodendrogliomas and oligoastrocytomas who had DWI, PWI, and MR spectroscopy at short and long TE data and known 1p/19q status. Univariate analyses and multivariate random forest models were performed to determine which criteria could differentiate between grades and genotypes.

**RESULTS:** ADC, rCBV, rCBF, and rK2 were significantly different between grade II and III oligodendroglial tumors. DWI, PWI, and MR spectroscopy showed no significant difference between tumors with and without 1p/19q loss. Separation between tumor grades and genotypes with cMRI alone showed 31% and 48% misclassification rates, respectively. Multimodal MR imaging helps to determine tumor grade and 1p/19q genotype more accurately (misclassification rates of 17% and 40%, respectively).

**CONCLUSIONS:** Although multimodal investigation of oligodendroglial tumors has a lower contribution to 1p/19q genotyping compared with cMRI alone, it greatly improves the accuracy of grading of these neoplasms. Use of multimodal MR imaging could thus provide valuable information that may assist clinicians in patient preoperative management and treatment decision making.

**ABBREVIATIONS:** cMRI = conventional MRI; Glx = complex glutamine/glutamate; K2 = permeability index; WHO = World Health Organization

**P**retherapeutic differentiation of WHO grade II and grade III oligodendroglial tumors is clinically important for establishing an appropriate therapy scheme and for patient management. Thus, grade II tumors may be treated with either radiation therapy or chemotherapy alone, whereas grade III tumors are generally treated more aggressively with a regimen of chemotherapy and/or radiation therapy with this depending on their 1p/19q

status. This genetic alteration, related to an unbalanced reciprocal translocation  $t(1;19)(q10;p10)$ ,<sup>1</sup> has been shown to predict better prognosis and response to radiotherapy and chemotherapy, in addition to longer survival duration for patients.<sup>2,3</sup> Although histopathology examination remains the reference standard method for the diagnosis and classification of brain tumors, variations in tissue sampling for these heterogeneous neoplasms and restrictions on surgical accessibility make it difficult to be certain that the samples analyzed are really representative of the entire tumor.<sup>4</sup>

Nowadays, cMRI is considered the reference standard for pretherapeutic noninvasive diagnosis and for providing helpful information for treatment decision making in brain tumors. However, its ability to differentiate between oligodendroglial tumor genotypes and grades is limited and can result in ambiguous (Fig. 1) or misleading results in some cases, because both grade II and grade III tumors may present similar clinical and MR imaging features.<sup>5,6</sup> Moreover, cMRI does not provide information on angiogenesis, metabolism, or cellularity, which are important parameters in tumor studies.


Received June 1, 2012; accepted after revision August 12.

From the Centre de Résonance Magnétique Biologique et Médicale (CRMBM) (S.F., P.J.C., S.C.-G., V.C.), Center for Research in Oncobiology and Oncopharmacology (CRO2) (D.F.-B.), and Mathematics Department (B.G.), Aix-Marseille University, Marseille, France; and Departments of Neuroradiology (D.C., P.D.-L., N.G.), Pathology and Neuropathology (A.M.D.P., D.F.-B.), Neurooncology (O.C.), and Neurosurgery (P.M.), APHM, Hôpital de la Timone, Marseille, France.

Paper previously presented at: Annual Meeting of the International Society for Magnetic Resonance in Medicine, May 7, 2012; Melbourne, Australia.

Please address correspondence to Slim Fellah, Centre de Résonance Magnétique Biologique et Médicale (CRMBM), UMR 7339 CNRS-Aix-Marseille University, Faculté de Médecine, 27, Boulevard Jean Moulin, 13385 Marseille cedex 5; e-mail: slim.fellah@univ-amu.fr

<http://dx.doi.org/10.3174/ajnr.A3352>



**FIG 1.** Confounding examples of grade II and grade III oligodendrogliomas and oligoastrocytomas by cMRI.

Diffusion-weighted imaging, perfusion-weighted imaging, and MR spectroscopy are increasingly used in the investigation of gliomas<sup>6-9</sup> because of their ability to sample not only the lesion but also the adjacent brain tissue for physiologic and metabolic alterations. Several studies<sup>7,10-14</sup> have managed to characterize and distinguish the molecular genotypes of gliomas by using conventional and/or advanced MR imaging techniques. However, to the best of our knowledge, no study has combined all of these MR imaging techniques to distinguish molecular features of grade II and grade III oligodendroglial tumors.

Thus, the aim of this study was to determine whether the combination of conventional and parametric MR imaging methods, obtained through routine pretherapy MR imaging examinations, could help classify oligodendroglial tumors according to their grade and genotype.

## **MATERIALS AND METHODS**

### **Study Population**

We retrospectively reviewed all adult patients who had been referred for an intracranial tumor between 2006 and 2010. From a

total of 270 patients, we included all who fulfilled the following criteria: 1) histologic diagnosis of grade II or III gliomas<sup>15</sup>; 2) MR imaging scans performed at initial diagnosis, before any intervention and including short and long TE MR spectroscopy, DWI, and PWI; and 3) known 1p/19q codeletion status. Overall, 50 patients (25 women and 25 men; median age,  $43.0 \pm 15.6$  years; age range, 18–82 years) met these criteria and were included in this study. In this population, 24 grade II tumors (10 oligodendrogliomas and 14 oligoastrocytomas) and 26 grade III tumors (12 oligodendrogliomas and 14 oligoastrocytomas) were identified. No pure astrocytomas fulfilled the inclusion criteria.

### **Histopathology and Molecular Genetics Studies**

The histopathologic diagnosis for each patient was made according to the latest WHO guidelines.<sup>15</sup> Chromosomal arms 1p and 19q copy numbers were determined by fluorescence in situ hybridization with locus-specific probes for 1p36 and 19q13, as described elsewhere.<sup>16</sup> No individual investigation of 1p or 19q was considered.

### MR Imaging Protocol

MR imaging was performed on a 1.5T scanner (Symphony; Siemens, Erlangen, Germany) equipped with an 8-channel phased-array head coil. Pretherapeutic cMRI protocol included the following sequences: sagittal flash gradient-echo T1 (TR, 376 ms; TE, 4.48 ms; section thickness, 4 mm; FOV, 300 mm), axial turbo spin-echo T2 (TR, 7240 ms; TE, 124 ms; section thickness, 4 mm; FOV, 240 mm), axial gradient-echo T2\* (TR, 1000 ms; TE, 17 ms; section thickness, 5 mm; FOV, 240 mm), coronal fluid-attenuated inversion recovery (TR, 8220 ms; TE, 112 ms; section thickness, 4.5 mm; FOV, 230 mm), and 3D T1 postcontrast (TR, 1880 ms; TE, 2.62 ms; section thickness, 1 mm; FOV, 256 mm).

We obtained diffusion-weighted images by using an axial echo-planar spin-echo sequence (TR, 3500; TE, 101 ms; section thickness, 5 mm; FOV, 254 mm). Diffusion was measured in 3 orthogonal directions by use of 3 b-values (0, 500, and 1000 s/mm<sup>2</sup>).

We obtained monovoxel MR spectroscopy data from all patients by using a volume of interest of 8 cm<sup>3</sup> (20 × 20 × 20 mm) that was centered in the bulk of the tumor, away from the scalp and the temporal bone. Spectra were acquired with a point-resolved spectroscopy sequence with short (30 ms) and long (135 ms) TE (TR, 1500 ms). An H<sub>2</sub>O signal was acquired for quantification purposes, at the same location.

Dynamic susceptibility contrast echo-planar gradient-echo images were acquired in all patients (TR, 1480 ms; TE, 30 ms; section thickness, 5 mm; FOV, 281 mm; 50 time points). A single standard dose (0.1 mmol/kg of body weight) of gadolinium (Dotarem, Guerbet, France) followed by 20 mL of saline solution was rapidly administered intravenously through a power injector at 6 mL/s.

### Postprocessing and Data Analysis

Two investigators, blinded to molecular and histologic data, evaluated the MR images by consensus. Necrosis, hemorrhage, and vasogenic edema were binary coded (0 when absent and 1 when present). Tumor border score was 0 or 1 (indistinct vs sharp) and was determined on T1 and T2 images. Contrast enhancement was coded with a score from 0 to 4—indicating absent, blurry, nodular, and ringlike, respectively. Tumor location was coded as frontal, temporal, insular (when involving the frontal and/or parietal lobes and the insula), temporoinsular, parietal, and thalamic.

Postprocessing of MR spectroscopy data was performed by use of the AMARES (advanced method for accurate, robust, and efficient spectral fitting) code<sup>17</sup> included in CSIPO, a homemade software package developed under the IDL environment (Research System, Boulder, Colorado). *N*-acetylaspartate (2.02 ppm), choline (3.22 ppm), creatine (3.03 ppm), and lactate (1.35 ppm) peaks were identified on the long and/or short echo time spectra. In addition, myo-inositol (3.56 ppm), lipids (0.85 and 1.70 ppm), and the Glx (2.16 and 2.28 ppm) peaks were determined on the MR spectra at short TE. MR spectroscopy relative quantification consisted of normalizing each metabolite by the water signal. The metabolite ratios NAA/Cho, Cho/Cr, NAA/Cr, and myo-inositol/Cr at long and/or short TE were also calculated.

The constructor console was used to generate apparent diffusion coefficient maps on a pixel-by-pixel basis. We conducted

postprocessing using PerfScape and NeuroScape software packages (Olea Medical, La Ciotat, France). CBF, corrected CBV, and K2 maps were generated after verification of the automatically detected arterial input function.

Multiple tumor regions of interest were manually drawn on the most representative section for both DWI and PWI modalities, and a single circular region of interest was placed over the mirrored normal brain in the contralateral hemisphere to obtain control values. Evaluation of ADC maps was carried out as follows: several ROIs were drawn inside of the tumor; cystic, necrotic, and hemorrhagic components were avoided whenever possible. The lowest ADC value, believed to represent high cellularity, was used to compare between grades and between genotypes. A similar method was used to investigate relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), and rK2 maps. Tumor ROIs were placed over the tumor areas with the highest blood volume, a method which has been shown to give the best interobserver and intraobserver reproducibility.<sup>19</sup> These ROIs were automatically replicated on rCBF and rK2 maps. In a similar fashion, the region of interest with the highest rCBV value was selected to represent the tumor. We then obtained diffusion and perfusion relative quantification by normalizing the tumor value of each parameter (CBF, CBV, and K2) by the corresponding contralateral value to obtain relative data (rCBF, rCBV, and rK2, respectively).

### Statistical Analysis

We performed univariate statistical analyses using JMP9 software (SAS Institute, Cary, North Carolina). Differences in ADC between tumor grades (grade II vs grade III) and tumor genotypes (1p/19q codeletion vs wild type) were assessed with the Student *t* test. When normality could not be verified, the nonparametric Wilcoxon test was used to evaluate differences in perfusion and spectroscopic quantitative parameters among groups. The 2-tailed Fisher exact test (when 1 subgroup was *n* < 5) and the Pearson  $\chi^2$  test were used to evaluate the significance of correlations between grade or genotype and cMRI parameters, genotype and histopathology findings, and genotype and tumor grade. A *P* value < .05 was chosen to indicate a statistically significant difference.

Multivariate analyses were performed by random forest,<sup>20</sup> a learning classifier, to predict group membership either for tumor grade or for genotype, with the 6 variables for cMRI or with the 19 variables for multimodal MR imaging as predictors (randomforest Package from R software v.2.13.0, <http://www.r-project.org/>).

A random forest is a collection of trees constructed over bootstrap samples of the original dataset. For each forest, we used the following values for the tuning parameters. Each tree was grown up to 1 observation per leaf (minimum size = 1). The splits of every node in a tree were optimized over  $m_{try} = \sqrt{M}$  explanatory variables chosen at random among the *M* variables included in the model (where *M* is the number of predictors). A total of 500 trees were used for each forest.

For a new observation, the final prediction of a random forest is given by a majority vote from all individually trained trees. To assess the accuracy of the forest, we randomly split the data into 2 disjointed samples: the learning sample and the test sample (two-



**Table 1: Histopathologic and cMRI features of the tumors**

	Grade II Oligoastrocytomas (n = 14)	Grade II Oligodendrogliomas (n = 10)	All Grade II (n = 24)	Grade III Oligoastrocytomas (n = 14)	Grade III Oligodendrogliomas (n = 12)	All Grade III (n = 26)	Total (n = 50)
Contrast enhancement							
Absent	8	7	15 (62.5%)	2	1	3 (11.5%)	18 (36%)
Blurry	6	2	8 (33.3%)	6	5	11 (42.4%)	19 (38%)
Nodular	0	1	1 (4.2%)	4	1	5 (19.2%)	6 (12%)
Ringlike	0	0	0 (0%)	2	5	7 (26.9%)	7 (14%)
Location							
Frontal	3	3	6 (25%)	6	6	12 (46.2%)	18 (36%)
Temporal	1	2	3 (12.5%)	3	3	6 (23.1%)	9 (18%)
Insular	2	4	6 (25%)	3	2	5 (19.2%)	11 (22%)
Temporoinsular	7	1	8 (33.3%)	1	1	2 (7.7%)	10 (20%)
Parietal	1	0	1 (4.2%)	0	0	0 (0%)	1 (2%)
Thalamic	0	0	0 (0%)	1	0	1 (3.8%)	1 (2%)
Tumor borders							
Sharp	6	3	9 (37.5%)	5	4	9 (34.6%)	18 (36%)
Indistinct	8	7	15 (62.5%)	9	8	17 (65.4%)	32 (64%)
Edema							
Yes	9	8	17 (70.9%)	9	7	16 (61.5%)	33 (66%)
No	5	2	7 (29.1%)	5	5	10 (38.5%)	17 (34%)
Necrosis							
Yes	8	4	12 (50%)	6	9	15 (57.7%)	27 (54%)
No	6	6	12 (50%)	8	3	11 (42.3%)	23 (46%)
Hemorrhage							
Yes	0	0	0 (0%)	1	4	5 (19.2%)	5 (10%)
No	14	10	24 (100%)	13	8	21 (80.8%)	45 (90%)
1p/19q loss							
Yes	4	9	13 (54.2%)	0	6	6 (23.1%)	19 (38%)
No	10	1	11 (45.8%)	14	6	20 (76.9%)	31 (62%)

thirds of the data for learning the model and the rest of the data for assessing its performance). The performance of the forest was assessed with use of the average of the misclassification error, more than 100 test samples. This was done for both models estimated by the cMRI and multimodal MR imaging variables.

The misclassification error rate, sensitivity, specificity, and the positive and negative predictive values of cMRI and multimodal MR imaging were defined on the basis of prediction results of the random forest to quantify the performance of the classification.

## RESULTS

The main histopathologic and cMRI characteristics of the tumors are summarized in Table 1. Most of the lesions were infiltrating and were located in the frontal lobe followed by the insula, the temporoinsular lobe, and the temporal lobe. More than half of the tumors were enhanced after injection of a contrast agent. Loss of 1p/19q was found in 38% of patients. Data from DWI, PWI, and MR spectroscopy are summarized in Table 2.

### Grade II vs Grade III

Hemorrhage was found in 5 patients with grade III tumors, but hemorrhage was absent in all patients with grade II tumors ( $P = .023$ ). Contrast enhancement was usually absent in grade II (15/24) compared with grade III neoplasms (3/26;  $P = .0004$ ). Ringlike enhancement was seen exclusively in grade III oligodendroglial tumors (7/26). ADC values were significantly higher in grade II compared with grade III tumors ( $P = .0008$ ), whereas rCBV, rCBF, and rK2 were lower in grade II tumors ( $P < .0001$  for all 3 measurements; Fig. 2, Table 2). NAA/H<sub>2</sub>O and NAA/Cho ratios at short TE were significantly higher in grade II tumors, but the

Cho/Cr ratio was significantly higher in grade III tumors ( $P = .023$ ;  $P = .034$ ; and  $P = .020$ , respectively). However, no cutoff value was found with DWI, PWI, and MR spectroscopy to accurately discriminate grade II from grade III oligodendroglial tumors.

### 1p/19q Codeletion vs 1p/19q Intact

Tumors with intact 1p/19q were mostly located in the temporal, insular, and temporoinsular regions (20/31), whereas those presenting with 1p/19q codeletion were more likely to be frontal (9/19; results not statistically significant). None of the oligodendroglial tumors with 1p/19q codeletion was located in the temporoinsular region. Nevertheless, 9 of 31 tumors with intact 1p/19q were located in the frontal lobe, and 6 of 19 tumors with 1p/19q loss were found in the insular area.

Neoplasms with 1p/19q codeletion were associated with the oligodendrogloma histologic type (15/19;  $P = .0001$ ) and grade II tumors (13/19;  $P = .023$ ), whereas nondeleted tumors correlated with oligoastrocytoma (24/31;  $P = .0001$ ) and grade III tumors (20/31;  $P = .023$ ). All grade III oligoastrocytomas had intact 1p/19q. Independent of tumor histologic grade, there was no significant difference in ADC, rCBV, rCBF, rK2, and metabolite ratios between tumors with 1p/19q loss and those with intact 1p/19q ( $P > .05$ ). This finding was also true when grade III tumors alone were considered. However, when only grade II oligodendroglial tumors were selected, rCBV and rCBF values were statistically higher in tumors presenting with 1p/19q codeletion compared with tumors without the deletions (Fig. 3;  $P = .0009$  and  $P = .0007$ , respectively). Statistical analysis of MR spectroscopy data

**Table 2: DWI, PWI, and MRS measurements in grade II and grade III oligodendroglial tumors and genotypes according to grade**


Parameter	Grade			Grade and Deletions			
	II (n = 24)	III (n = 26)	P value	Grade II with 1p/19q Loss (n = 13)	Grade II with Intact 1p/19q (n = 11)	Grade III with 1p/19q Loss (n = 6)	Grade III with Intact 1p/19q (n = 20)
ADC ( $10^{-3}$ mm <sup>2</sup> /s)	1238.50 ± 208.42	995.19 ± 266.97	.0008	1181.9 ± 201.32	1305.4 ± 205.38	1059.16 ± 127.21 <sup>b</sup>	976 ± 296.38 <sup>a,b</sup>
rADC	1.66 ± 0.29	1.3 ± 0.29	< .0001	1.57 ± 0.22	1.77 ± 0.33	1.49 ± 0.15	1.24 ± 0.3 <sup>a,b</sup>
rCBV	1.57 ± 0.82	3.89 ± 1.97	< .0001	2.09 ± 0.73	0.95 ± 0.33 <sup>a</sup>	4.43 ± 2.38 <sup>a,b</sup>	3.72 ± 1.86 <sup>a,b</sup>
rCBF	1.65 ± 0.97	4.12 ± 2.15	< .0001	2.21 ± 0.92	0.98 ± 0.48 <sup>a</sup>	4.87 ± 3.36 <sup>a,b</sup>	3.89 ± 1.69 <sup>a,b</sup>
rK2	5.18 ± 7.26	13.64 ± 9.86	< .0001	6.5 ± 8.14	3.57 ± 6.05	12.65 ± 12.59 <sup>b</sup>	13.93 ± 9.27 <sup>a,b</sup>
NAA/H <sub>2</sub> O <sup>c</sup>	3.19 ± 1.52	2.39 ± 0.71	.023	3.20 ± 1.13	3.18 ± 1.96	2.53 ± 0.62	2.34 ± 0.75 <sup>a</sup>
Cr/H <sub>2</sub> O <sup>c</sup>	3.24 ± 1.37	2.84 ± 1.13	.472	3.03 ± 0.94	3.5 ± 1.77	2.8 ± 0.86	2.86 ± 1.22
Cho/H <sub>2</sub> O <sup>c</sup>	3.87 ± 1.18	4.81 ± 2.65	.26	3.74 ± 0.82	4.03 ± 1.53	4.75 ± 1.28	4.83 ± 2.97
mIns/H <sub>2</sub> O <sup>c</sup>	2.27 ± 2.16	1.77 ± 1.19	.669	2.09 ± 1.6	2.49 ± 2.76	1.5 ± 0.53	1.84 ± 1.33
Glx/H <sub>2</sub> O <sup>c</sup>	8.54 ± 2.96	7.94 ± 2.82	.69	8.92 ± 2.74	2.08 ± 3.27	7.83 ± 1.63	7.97 ± 3.12
Lipids/H <sub>2</sub> O <sup>c</sup>	14.25 ± 16.07	15.88 ± 28.40	.969	19.13 ± 20.76	8.48 ± 3.02	11.76 ± 5.89	17.11 ± 32.32
NAA/Cr <sup>c</sup>	1.02 ± 0.38	0.99 ± 0.61	.145	1.11 ± 0.40	0.91 ± 0.34	0.98 ± 0.35	0.99 ± 0.67 <sup>a</sup>
Cho/Cr <sup>c</sup>	1.33 ± 0.55	1.80 ± 1.00	.034	1.42 ± 0.69	1.22 ± 0.33	2.14 ± 1.81	1.7 ± 0.64 <sup>b</sup>
NAA/Cho <sup>c</sup>	0.86 ± 0.41	0.64 ± 0.40	.02	0.91 ± 0.48	0.8 ± 0.34	0.59 ± 0.27 <sup>a</sup>	0.66 ± 0.43
mIns/Cr <sup>c</sup>	0.67 ± 0.41	0.58 ± 0.31	.846	0.72 ± 0.5	0.61 ± 0.28	0.56 ± 0.14	0.59 ± 0.35

**Note:**—mIns indicates myo-inositol; rADC, relative apparent diffusion coefficient; rCBV, relative cerebral blood volume; rCBF, relative cerebral blood flow; rK2, relative permeability index.

<sup>a</sup> Significantly different from grade II with 1p/19q loss ( $P < .05$ ).

<sup>b</sup> Significantly different from grade II with intact 1p/19q ( $P < .05$ ).

<sup>c</sup> Short TE.



**FIG 2.** Boxplots show significant differences in rCBV, rCBF, rK2, and ADC between grade II and grade III oligodendroglial tumors: (A) rCBV, (B) rCBF, and (C) rK2 are significantly higher in grade III compared with grade II tumors, whereas (D) ADC is significantly increased in grade II tumors.

showed no significant difference between tumors with the 1p/19q genotype and those with intact 1p/19q.

### Multivariate Analysis

Table 3 shows the sensitivity, specificity, positive and negative predictive values, as well as misclassification error rates of cMRI and multimodal MR imaging in the prediction of tumor grade and genotype. Random forest analysis with cMRI alone, including contrast enhancement, tumor location, necrosis, hemorrhage, edema, and tumor borders, showed a high misclassification error rate of 31% for tumor grading. A better classification of the patients according to tumor grade was obtained when combining

cMRI, DWI, PWI, and MR spectroscopy at short TE with a 17% misclassification error rate (Table 3).


In a similar fashion, when cMRI alone was considered, 48% of patients could not be classified according to 1p/19q genotype (deleted vs intact 1p/19q). A slightly better discrimination was obtained by multimodal MR imaging with 40% misclassification error (Table 3).

When both tumor grade and genotype were combined (ie, 4 groups: grade II with 1p19q loss, grade II with 1p19q intact, grade III with 1p19q loss, and grade III with 1p19q intact), the random forest analysis performed by multimodal MR imaging showed an increased classification accuracy (61%) compared with results obtained with cMRI alone (45%).

### DISCUSSION

Although treatment strategy for grade II and grade III oligodendrogliomas and oligoastrocytomas is currently evolving, the optimal management of these tumors has yet to be defined. Tumor genetic profile and histologic grade are currently the 2 most important factors in therapeutic decision making for patients with these neoplasms. In our present study, we were interested in determining whether the combination of PWI, DWI, and single-voxel MR spectroscopy with cMRI could help classify oligodendroglial tumors according to their histopathologic grade and genotype.

Indeed, radiologic grading of tumors with cMRI is not always accurate, with a sensitivity in identifying high-grade gliomas ranging from 55% to 83%.<sup>5,6,21</sup> It is even more challenging to



**FIG 3.** Boxplots show that grade II tumors with 1p/19q codeletion have significantly higher rCBV and rCBF than tumors with intact 1p/19q. No significant difference could be observed between genotypes in grade III oligodendroglial tumors.

differentiate grade III from grade II oligodendroglial tumors by using cMRI, as also observed in our study (sensitivity, 65%). However, a combination of cMRI, diffusion, perfusion, and short TE MR spectroscopy data greatly helped to grade oligodendroglial tumors (sensitivity, 82%). Although anaplastic tumors generally tend to enhance after injection of contrast medium, contrast enhancement is not specific enough and does not correlate with tumor grade<sup>12,14,22</sup> or molecular profile.<sup>12,23</sup> As seen in this study, oligodendroglial tumors located in the insular and the temporo-insular regions were more likely to harbor intact 1p/19q. However, unlike previous reports,<sup>16,24</sup> no significant correlation between tumor location and 1p/19q status has been found.

Although ADC values were significantly higher in grade II compared with grade III tumors, as previously reported,<sup>25</sup> no significant association between ADC and 1p/19q status was found. These results differ from those published by Jenkinson et al<sup>10</sup> in a study of 17 gliomas in which the authors reported no statistically

significant difference between grade II and III tumors and showed that tumors with 1p/19q loss were more likely to have lower maximal ADC and mean histogram ADC compared with those with intact 1p/19q. This disparity in results could be explained by the variations in the number of patients included (50 in our study vs 17 in the Jenkinson et al study) and by different diffusion parameters assessed in our study and the Jenkinson et al study.

Our results demonstrated a significantly higher rCBV in grade III compared with grade II oligodendroglial tumors. These findings are in concordance with those reported in several,<sup>14,26,27</sup> but not all,<sup>7,25,28</sup> studies. Unlike the aforementioned studies, in which the authors reported no significant difference in rCBV between grade II and III gliomas, our patient population was more equally distributed. Moreover, our data show that increased rCBV is associated with 1p/19q codeletion in grade II, but not grade III, tumors—an observation that has been reported in few studies.<sup>14,26</sup> This finding implies that tumor vascularity is not always predictive of high malignancy, especially in oligodendrogliomas and oligoastrocytomas. Although vascular permeability and blood flow were rarely investigated in previous series of gliomas,<sup>8,29</sup> our study shows that rCBV, rCBF, and rK<sub>2</sub> from PWI could be significantly different between grade II and III oligodendroglial tumors and between genotypes when only grade II tumors are considered (rCBV and rCBF).

Single-voxel and multi-voxel proton MR spectroscopy have already been used for assessment and grading of gliomas.<sup>6,9,27,30</sup> Single-voxel MR spectroscopy could be a disadvantage compared with multi-voxel MR spectroscopy in the exploration of oligodendroglial tumors, particularly because of the heterogeneity of these neoplasms in which it would be very interesting to investigate the entire lesion. However, multi-voxel MR spectroscopy would require longer acquisition time; robust sequence would have to be available (with accurate saturation band to avoid peripheral fat contamination); and more complex postprocessing is required, which is not always consistent with clinical settings. As previously reported,<sup>9,27</sup> Cho/Cr and Cho/NAA ratios were significantly higher in grade III compared with grade II oligodendroglial tumors. Elevated Cho levels indicate increased membrane synthesis and increased cellularity,<sup>31,32</sup> which are characteristics of high-grade gliomas.<sup>15</sup> Oligodendroglial tumors with or without 1p/19q deletions could not be distinguished by metabolite ratios, which suggests that investigated metabolites do not contribute to the differences in clinical behavior.<sup>13</sup>

**Table 3: Sensitivity, specificity, PPV, NPV, and misclassification error rate in the differentiation of tumor grades and genotypes**

Sensitivity/Specificity, PPV/NPV	cMRI <sup>a</sup>	Multimodal MRI <sup>b,c</sup>
Grade <sup>b</sup>		
II	73/65%, 67/72%	84/82%, 82/84%
III	65/73%, 72/67%	82/84%, 84/82%
Misclassification error rate	31%	17%
Genotype <sup>c</sup>		
1p/19q Loss	23/70%, 33/59%	29/79%, 46/64%
1p/19q Intact	70/23%, 59/33%	79/29%, 64/46%
Misclassification error rate	48%	40%

**Note:**—CE indicates contrast enhancement; NPV, negative predictive value; PPV, positive predictive value.

The 6 most important predictors arising from the random forest analyses are:

<sup>a</sup> CE+Location+Necrosis+Hemorrhage+Edema+Tumor borders

<sup>b</sup> rCBF+rCBV+CE+ADC+Hemorrhage+ NAA/Cho at short TE

<sup>c</sup> Location+ADC+rCBF+Cho/H<sub>2</sub>O+ NAA/Cr+lipids/H<sub>2</sub>O at short TE.

Finally, in our study, random forest statistical analysis has shown that multimodal MR imaging (17% misclassification error and 82% sensitivity to distinguish grade III from grade II) could notably improve the classification accuracy of patients with oligodendroglial tumors according to tumor grade compared with cMRI alone (31% misclassification error and 65% sensitivity to distinguish grade III from grade II). This improvement in classification accuracy between multimodal MR imaging and cMRI was less marked in genotyping (40% misclassification error, and 79% sensitivity for multimodal MR imaging vs 48% misclassification error, and 70% sensitivity to separate 1p/19q intact from 1p/19q codeletion genotype for cMRI). This finding could be explained by absence of significant correlations between the 1p/19q molecular profile and the DWI, PWI (except rCBV and rCBF when only grade II tumors were considered), and MR spectroscopy parameters evaluated in this study and by the strong influence of tumor location on the genotyping accuracy.

Although random forest analysis could be used prospectively to give statistical prediction of grade or genotype, we do not intend to suggest its use for therapeutic decisions. Here, rather we aimed to evaluate the potential contribution of noninvasive multimodal MR techniques to the grading and genotyping of oligodendroglial tumors compared with cMRI. Multimodal MR imaging could also help in the preoperative treatment of patients, when complete resection cannot be performed, by guiding the biopsy to the more aggressive part of the tumor. However, for now, MR imaging is not intended to replace histopathologic examination, and any therapeutic decisions will be made after such examination. It is important to note that no additional contribution was found when we added long TE MR spectroscopy data to the analysis. Thus, when available scan time is limited, MR spectroscopy data at short TE should be acquired preferably to better differentiate between tumor grades and genotypes.

## CONCLUSIONS

Nowadays, histopathology examination is still the reference standard for grading and classifying brain tumors. Our method showed that combining perfusion, diffusion, and spectroscopy measurements with cMRI data, in pretherapeutic MR imaging scans, could improve the accuracy to discriminate grade III from grade II oligodendroglial tumors with a sensitivity and specificity

of 82% and 84%, respectively, but this multimodal investigation has a lower contribution to genotyping these tumors compared with cMRI alone. However, adding some advanced MR imaging techniques to cMRI could noninvasively provide valuable information that may assist clinicians in patient preoperative management and treatment decision making.

## ACKNOWLEDGMENTS

The authors express their gratitude to Patrick Viout for his great work on MR spectroscopy data postprocessing and Yann Le Fur for software development.

**Disclosures:** Olivier Chinot—UNRELATED: Consultancy: Roche; Payment for Lectures (including service on speakers bureaus): MSD; Patents (planned, pending, or issued): in the field of predictive markers or targeted therapies; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: for Congress. Nadine Girard—RELATED: Support for Travel to Meetings for the Study or Other Purposes: Olea Medical, Comments: the money is not paid directly to me; UNRELATED: Consultancy: Olea Medical, Comments: the money is not paid directly to me; travel expenses and hotel accommodations for scientific meetings.

## REFERENCES

- Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Res* 2006;66:9852–61
- Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *J Clin Oncol* 2000;18: 636–45
- Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. *Neurology* 2006;66:1661–67
- Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. *J Neuropathol Exp Neurol* 2002;61: 58–63
- Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. *Radiology* 1990;174:411–15
- Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. *AJNR Am J Neuroradiol* 2003;24:1989–98
- Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. *Neuroradiology* 2006;48:703–13
- Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. *AJNR Am J Neuroradiol* 2004;25:746–55
- Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. *Radiology* 2006;238: 958–69
- Jenkinson MD, Smith TS, Brodbelt AR, et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. *J Magn Reson Imaging* 2007;26:1405–12
- Law M, Brodsky JE, Babb J, et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. *J Magn Reson Imaging* 2007;25:1113–19
- Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. *Brain* 2006;129:1884–91
- Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. *Neurology* 2005;64:2085–89



14. Kapoor GS, Gocke TA, Chawla S, et al. **Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.** *J Neurooncol* 2009;92:373–86
15. Louis DN, Ohgaki H, Wiestler OD, et al. **The 2007 WHO classification of tumours of the central nervous system.** *Acta Neuropathol* 2007;114:97–109
16. Metellus P, Coulibaly B, Colin C, et al. **Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.** *Acta Neuropathol* 2010;120:719–29
17. Vanhamme L, van den Boogaart A, Van Huffel S. **Improved method for accurate and efficient quantification of MRS data with use of prior knowledge.** *J Magn Reson* 1997;129:35–43
18. Le Fur Y, Nicoli F, Guye M, et al. **Grid-free interactive and automated data processing for MR chemical shift imaging data.** *MAGMA* 2010;23:23–30
19. Wetzel SG, Cha S, Johnson G, et al. **Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study.** *Radiology* 2002;224:797–803
20. Breiman L. **Random forests.** *Machine Learning* 2001;45:5–32
21. Möller-Hartmann W, Herminghaus S, Krings T, et al. **Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions.** *Neuroradiology* 2002;44:371–81
22. White ML, Zhang Y, Kirby P, et al. **Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?** *AJNR Am J Neuroradiol* 2005;26:784–90
23. Megyesi JF, Kachur E, Lee DH, et al. **Imaging correlates of molecular signatures in oligodendrogliomas.** *Clin Cancer Res* 2004;10:4303–06
24. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. **Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.** *Cancer Res* 2001;61:6713–15
25. Hilario A, Ramos A, Perez-Núñez A, et al. **The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas.** *AJNR Am J Neuroradiol* 2012;33:701–07
26. Whitmore RG, Krejza J, Kapoor GS, et al. **Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.** *J Neurosurg* 2007;107:600–09
27. Spampinato MV, Smith JK, Kwock L, et al. **Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.** *AJR Am J Roentgenol* 2007;188:204–12
28. Xu M, See SJ, Ng WH, et al. **Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.** *Neurosurgery* 2005;56:919–26; discussion 919–26
29. Chawla S, Wang S, Wolf RL, et al. **Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas.** *AJNR Am J Neuroradiol* 2007;28:1683–89
30. Galanaud D, Nicoli F, Chinot O, et al. **Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy.** *Magn Reson Med* 2006;55:1236–45
31. Smith JK, Castillo M, Kwock L. **MR spectroscopy of brain tumors.** *Magn Reson Imaging Clin N Am* 2003;11:415–29, v–vi
32. Gupta RK, Cloughesy TF, Sinha U, et al. **Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.** *J Neurooncol* 2000;50:215–26